Mark J. Vignola Sells 9,059 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Mark J. Vignola sold 9,059 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $5.80, for a total value of $52,542.20. Following the sale, the chief financial officer now directly owns 74,752 shares of the company's stock, valued at $433,561.60. This represents a 10.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Terns Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:TERN traded down $0.04 during midday trading on Monday, reaching $5.71. 1,252,259 shares of the company were exchanged, compared to its average volume of 1,424,849. The stock has a market cap of $485.00 million, a PE ratio of -4.84 and a beta of -0.31. The business's fifty day moving average is $6.35 and its two-hundred day moving average is $7.41. Terns Pharmaceuticals, Inc. has a one year low of $4.32 and a one year high of $11.40.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05. As a group, sell-side analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

Institutional Investors Weigh In On Terns Pharmaceuticals

Several large investors have recently bought and sold shares of the business. nVerses Capital LLC bought a new position in Terns Pharmaceuticals during the third quarter valued at $48,000. Sio Capital Management LLC bought a new position in Terns Pharmaceuticals during the 3rd quarter valued at about $83,000. Entropy Technologies LP bought a new position in Terns Pharmaceuticals during the 3rd quarter valued at about $106,000. Bleakley Financial Group LLC raised its position in Terns Pharmaceuticals by 26.0% in the 3rd quarter. Bleakley Financial Group LLC now owns 13,312 shares of the company's stock worth $111,000 after purchasing an additional 2,751 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Terns Pharmaceuticals by 78.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,535 shares of the company's stock worth $113,000 after purchasing an additional 5,935 shares during the last quarter. Institutional investors own 98.26% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TERN shares. BMO Capital Markets reissued an "outperform" rating and issued a $26.00 target price (up from $19.00) on shares of Terns Pharmaceuticals in a report on Monday, September 16th. JMP Securities reissued a "market outperform" rating and issued a $20.00 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. Oppenheimer lifted their target price on shares of Terns Pharmaceuticals from $17.00 to $20.00 and gave the company an "outperform" rating in a research note on Wednesday, December 4th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $7.50 price target on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $18.30.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.